TRACON Enters Strategic Collaboration with Janssen

San Diego – October 6, 2016 – Cooley advised TRACON Pharmaceuticals on its strategic licensing collaboration with Janssen Pharmaceutical for two novel oncology assets and on its $5 million equity investment from Johnson & Johnson Innovation – JJDC.

The transaction grants TRACON the rights to develop two Janssen oncology programs: TRC253, a novel small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, intended for the treatment of men with prostate cancer; and TRC694, a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase, intended for the treatment of patients with hematologic malignancies including myeloma.

TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age‐related macular degeneration and fibrotic diseases. Janssen is a pharmaceutical company headquartered in Belgium.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.